Zevin Asset Management LLC Sells 16,144 Shares of GSK plc (NYSE:GSK)

Zevin Asset Management LLC trimmed its stake in GSK plc (NYSE:GSK – Get Rating) by 23.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 53,806 shares of the pharmaceutical company’s stock after selling 16,144 shares during the period. Zevin Asset Management LLC’s holdings in GSK were worth $1,584,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Pflug Koory LLC acquired a new position in GSK in the 3rd quarter valued at approximately $26,000. Castle Wealth Management LLC acquired a new position in shares of GSK in the second quarter valued at $28,000. Householder Group Estate & Retirement Specialist LLC bought a new position in GSK in the third quarter worth $31,000. CX Institutional acquired a new stake in GSK during the second quarter worth $32,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC increased its holdings in GSK by 61.3% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock valued at $42,000 after buying an additional 368 shares during the period. Institutional investors and hedge funds own 13.15% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. UBS Group lowered shares of GSK from a “neutral” rating to a “sell” rating in a research report on Friday, November 11th. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 26th. JPMorgan Chase & Co. lowered GSK from a “neutral” rating to an “underweight” rating in a research note on Tuesday, January 3rd. Bank of America lowered shares of GSK from a “neutral” rating to an “underperform” rating in a report on Monday, December 5th. Finally, Morgan Stanley cut their price target on shares of GSK from GBX 1,650 ($20.38) to GBX 1,535 ($18.96) in a report on Wednesday, November 30th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, GSK currently has a consensus rating of “Hold” and an average target price of $1,583.57.

GSK Trading Down 1.0 %

Shares of NYSE GSK traded down $0.37 during midday trading on Thursday, hitting $35.12. The stock had a trading volume of 986,569 shares, compared to its average volume of 3,889,717. The firm has a market cap of $71.89 billion, a P/E ratio of 4.34, a price-to-earnings-growth ratio of 1.22 and a beta of 0.64. GSK plc has a fifty-two week low of $28.47 and a fifty-two week high of $46.97. The company has a debt-to-equity ratio of 2.22, a current ratio of 0.97 and a quick ratio of 0.74. The company’s 50-day simple moving average is $35.18 and its 200 day simple moving average is $34.29.

GSK (NYSE:GSK – Get Rating) last announced its quarterly earnings data on Wednesday, November 2nd. The pharmaceutical company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.19. GSK had a return on equity of 32.18% and a net margin of 37.88%. The firm had revenue of $9.22 billion during the quarter, compared to analyst estimates of $7.75 billion. Research analysts anticipate that GSK plc will post 3.31 EPS for the current year.

GSK Company Profile

(Get Rating)

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.